Skip to content
Tafenoquine
Arakoda, Krintafel (tafenoquine) is a small molecule pharmaceutical. Tafenoquine was first approved as Krintafel on 2018-07-20. It is used to treat malaria in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Arakoda, Krintafel
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafenoquine succinate
Tradename
Company
Number
Date
Products
ARAKODA60 Degrees PharmaceuticalsN-210607 RX2018-08-08
1 products, RLD, RS
KRINTAFELGSKN-210795 RX2018-07-20
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
arakodaNew Drug Application2020-11-16
krintafelNew Drug Application2020-11-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
malariaEFO_0001068D008288B54
Agency Specific
FDA
EMA
Expiration
Code
TAFENOQUINE SUCCINATE, KRINTAFEL, GLAXOSMITHKLINE
2025-07-20ODE-201
2023-07-20NCE
TAFENOQUINE SUCCINATE, ARAKODA, 60 DEGREES PHARMS
2023-07-20NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Tafenoquine Succinate, Arakoda, 60 Degrees Pharms
103427912035-12-02U-2582
108885582035-12-02U-2582
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01B: Antimalarials
— P01BA: Aminoquinoline antimalarials
— P01BA07: Tafenoquine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAFENOQUINE
INNtafenoquine
Description
N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine is an aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group. It is a member of (trifluoromethyl)benzenes, an aminoquinoline, an aromatic ether, a primary amino compound and a secondary amino compound.
Classification
Small molecule
Drug classAntimalarial
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1
Identifiers
PDB—
CAS-ID106635-80-7
RxCUI—
ChEMBL IDCHEMBL298470
ChEBI ID—
PubChem CID115358
DrugBankDB06608
UNII ID262P8GS9L9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,033 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
27 adverse events reported
View more details